RxDoctor Payments Data

Anil Modi, MD

Internal Medicine · Lagrange, GANPI 1508868704

Payments from drug & device makers

$18,254in general payments, 2019–2025

Across 709 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$6K
  • Lilly USA, LLC$975
  • AbbVie$929
  • AstraZeneca$766
  • Novo Nordisk$762
  • Amgen$741
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,069100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS6$6,185
Lilly USA, LLC65$975
AbbVie(2 entities)66$929
AstraZeneca(2 entities)45$766
Novo Nordisk44$762
Amgen(2 entities)47$741
Pfizer31$595
Bayer25$471
Novartis26$415
Boehringer Ingelheim22$391
Abbott20$374
Scilex Pharmaceuticals Inc.31$366
Sanofi-aventis U.S. LLC22$330
Shield Therapeutics Inc15$312
Biogen17$287
Greenwich Biosciences, Inc.16$282
Sanofi14$261
Otsuka America Pharmaceutical, Inc.11$223
Eisai Inc.9$191
SK Life Science, Inc.9$184
Biohaven Pharmaceutical Holding Company Ltd.7$164
Amneal Pharmaceuticals LLC8$160
Lundbeck LLC7$153
Neurocrine Biosciences, Inc.7$148
Johnson & Johnson8$146
GSK7$146
Axsome Therapeutics, Inc.7$145
Teva Pharmaceuticals USA, Inc.7$126
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$124
Esperion Therapeutics, Inc.5$120
CSL Behring5$118
Biohaven Pharmaceuticals, Inc.7$118
Takeda Pharmaceuticals U.S.A., Inc.5$114
UCB, Inc.4$110
Avanir Pharmaceuticals, Inc.6$107
Amarin Pharma, Inc.6$105
Sunovion Pharmaceuticals Inc.7$99
Jazz Pharmaceuticals Inc.4$86
Acadia Pharmaceuticals Inc5$83
Xeris Pharmaceuticals, Inc.4$78
Merck6$77
Argenx US, Inc.3$69
Alfasigma USA, Inc.3$64
Idorsia Pharmaceuticals US Inc4$56
Grifols USA, LLC2$53
ANI Pharmaceuticals, Inc.2$52
EMD Serono, Inc.3$52
Upsher-smith Laboratories LLC3$50
Neurelis, Inc.2$37
Ironwood Pharmaceuticals, Inc2$34
Zyla Life Sciences, Inc.2$29
Acorda Therapeutics, Inc2$25
Mallinckrodt Enterprises LLC1$25
Catalyst Pharmaceuticals, Inc.1$22
GE HealthCare1$19
Kyowa Kirin, Inc.1$17
Mylan Specialty L.p.1$17
Livanova USA, Inc.1$16
Supernus Pharmaceuticals, Inc.1$16
MDD US Operations, LLC1$14

How this compares

$18,254 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$286,925
Medicare patients
316
Services billed
4,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$146,537
FarxigaDapagliflozin Propanediol89$88,846
OzempicSemaglutide43$82,348
JardianceEmpagliflozin68$67,456
MounjaroTirzepatide48$52,200
Xigduo XrDapaglifloz Propaned/Metformin41$44,755
TrulicityDulaglutide31$43,117
Soliqua 100-33Insulin Glargine/Lixisenatide25$41,017
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$40,260
Synjardy XrEmpagliflozin/Metformin Hcl49$33,886
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$26,751
XareltoRivaroxaban21$26,054
Tresiba Flextouch U-100Insulin Degludec33$24,785
RybelsusSemaglutide18$19,781
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$19,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$595$146,537203 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$766$134,198150 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr$391$115,713137 claims
Novo NordiskOzempic, Rybelsus$762$102,12961 claims
Lilly USA, LLCMounjaro, Trulicity$975$95,31779 claims
GSKTrelegy Ellipta, Breo Ellipta$146$55,11159 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$330$41,01725 claims
Johnson & JohnsonXarelto$146$26,05421 claims
AbbVieLinzess, Namzaric$929$16,11767 claims
MerckJanumet$77$16,05515 claims
NovartisEntresto$415$7,59111 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$160$6,016657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Lagrange

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →